Measurement of anti-phospholipid antibodies by ELISA using β2-glycoprotein I as an antigen

Arvieux, J.; Roussel, Bernard; Jacob, Marie‐Christine; Colomb, Maurice G.

doi:10.1016/0022-1759(91)90047-j

Cited by 206 publications

(115 citation statements)

References 17 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…In addition, anti-P,GPI antibodies have been found in patients with APS (15)(16)(17)(18)(19)(20)(21). It is unclear, however, whether the antibodies recognize the proteins themselves, the PL-protein complex, or neo-or cryptic antigens eventually expressed as a result of the interaction (20,21).…”

Section: Discussionmentioning

confidence: 99%

“…Anionic surfaces are thought to be able to cluster the antigens, thus facilitating the occurrence of so-called "monogamous bivalency" of the autoantibodies (21). CL-coated or y-irradiated plates seem to represent the best substrates to allow such a phenomenon (15)(16)(17)(18)(19)(20)(21)(41)(42)(43). Evidence from ex vivo and in vitro studies also indicates that EC membranes offer a suitable surface for p,GPI binding (27)(28)(29).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, antibodies reacting directly with p,GPI have been found. Both types of antibodies are thought to play a leading role in the pathogenesis of A P S since they closely correlate with the appearance of the typical clinical manifestations (15)(16)(17)(18)(19). Whether aPL-positive sera recognize epitopes displayed by P,GPI itself or whether the epitope consists of both P,GPI and cardiolipin (CL) is still open to discussion (20,21).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β₂‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β₂‐Glycoprotein I and Induce Endothelial Activation

Papa

Guidali

Sala

et al. 1997

Arthritis & Rheumatism

268

142

View full text Add to dashboard Cite

Objective. To investigate the ability of human anti-&-glycoprotein I (anti-&GPI) antibodies to recognize the cofactor adherent on endothelial cells (EC) and to modulate endothelial functions.Methods. Six human affinity-purified polyclonal anti-P,GPI IgG and 2 IgM monoclonal antibodies (MAb) were obtained from patients with the antiphospholipid syndrome. The antibodies were tested for their ability to 1) bind to endothelial monolayers through the adherent f3,GPI and 2) modulate endothelial adhesion molecule expression and interleukin-6 (IL-6) and 6-keto-prostaglandin F,, (6-keto-PGF1,) secretion.Results. The affinity-purified IgG and the MAb with anti-&GPI activity, but not the respective controls, displayed EC binding, which declined on cells incubated in serum-free medium and was restored in a dose-dependent manner by exogenous human P,GPI. After EC binding, both polycJonaJ and monoclonal antibodies up-regulated adhesion molecule expres-

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β₂‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β₂‐Glycoprotein I and Induce Endothelial Activation

Papa

Guidali

Sala

et al. 1997

Arthritis & Rheumatism

268

142

View full text Add to dashboard Cite

show abstract

“…Guerin et al (62), however, failed to absorb the antibody reactivity in APS sera when using up to 640 g/ml of ␤ 2 GPI in solution. In contrast, many other authors have found that sufficiently high concentrations of ␤ 2 GPI (ϳ400 g/ml) in free solution significantly reduce aPL binding to ␤ 2 GPI on ELISA plates, in a dose-dependent manner (25,58,(63)(64)(65)(66)(67). The evidence that native ␤ 2 GPI may be recognized by aPL in Western blotting experiments is conflicting; some authors demonstrate binding (68,69), but others do not (62,70,71).…”

Section: Molecular Structure and Function Of ␤ 2 Gpimentioning

confidence: 93%

How do antiphospholipid antibodies bind β₂‐glycoprotein I?

Giles¹,

Isenberg²,

Latchman³

et al. 2003

Arthritis & Rheumatism

View full text Add to dashboard Cite

“…IgG and IgM anti-b 2 -GPI antibodies were measured using an in-house-developed ELISA in accordance with the method of Arvieux et al (15).…”

Section: Detection Of Igg and Igm Anti-b 2 -Gpi Antibodiesmentioning

confidence: 99%

Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome

Grypiotis

Ruffatti

Pengo

et al. 2006

Clinical Laboratory Analysis

View full text Add to dashboard Cite

The silica clotting time (SCT) is a phospholipid-dependent coagulation assay used for the laboratory diagnosis of lupus anticoagulant (LA) antibodies. The sensitivity and specificity of a new commercial SCT for identifying LA in patients who meet the clinical criteria for antiphospholipid syndrome (APS), and its association with thrombotic events were evaluated here. Forty-five patients who met the clinical criteria for APS according to the Sapporo International Consensus Statement were examined. Sixty-nine patients who did not meet the clinical criteria for APS, and 20 blood donors were used as controls. Plasma samples from the patients and controls were tested for LA using a new commercial SCT with low and high synthetic phospholipid concentrations. The results were compared with those obtained by diluted Russell's viper venom time (dRVVT) and activated partial thromboplastin time (APTT). SCT's sensitivity for identifying LA in patients who met the clinical criteria of APS was higher compared to APTT and dRVVT (53.3% vs. 31.1% and 31.1%), and the specificities of these assays were 96.6%, 100%, and 98.9%, respectively. When dRVVT was combined with SCT, and dRVVT was combined with APTT their sensitivities were 57.7% and 48.8%, and their specificities were 96.6% and 98.9%, respectively. A stepwise logistic regression analysis indicated that the combination of dRVVT with SCT was associated with total thrombotic events (odds ratio (OR) 5 11.5, 95% confidence interval (CI) 5 1.25-106.3, P 5 0.031) as well as with venous thrombosis (OR 5 4.09, 95% CI 5 1.16-14.43, P 5 0.028). According to our results, SCT is the most sensitive assay for identifying LA in patients who meet the clinical criteria for APS. Moreover, the highest sensitivity was reached with a combination of SCT and dRVVT. The method's association with total thrombotic events and venous thrombosis was in fact significant.

show abstract

Measurement of anti-phospholipid antibodies by ELISA using β2-glycoprotein I as an antigen

Cited by 206 publications

References 17 publications

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β₂‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β₂‐Glycoprotein I and Induce Endothelial Activation

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β₂‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β₂‐Glycoprotein I and Induce Endothelial Activation

How do antiphospholipid antibodies bind β₂‐glycoprotein I?

Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome

Contact Info

Product

Resources

About

Measurement of anti-phospholipid antibodies by ELISA using β2-glycoprotein I as an antigen

Cited by 206 publications

References 17 publications

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β2‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2‐Glycoprotein I and Induce Endothelial Activation

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β2‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2‐Glycoprotein I and Induce Endothelial Activation

How do antiphospholipid antibodies bind β2‐glycoprotein I?

Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome

Contact Info

Product

Resources

About

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β₂‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β₂‐Glycoprotein I and Induce Endothelial Activation

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β₂‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β₂‐Glycoprotein I and Induce Endothelial Activation

How do antiphospholipid antibodies bind β₂‐glycoprotein I?